NCT07527858 2026-04-14
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer
Gilead Sciences
Phase 2 Not yet recruiting
Clinical Trials
15 trialsNCT07529873 2026-04-14
N'FORCE
Groupe Oncologie Radiotherapie Tete et Cou
Phase 2 Not yet recruiting
NCT07514767 2026-04-07
NOCANO
Karolinska University Hospital
Phase 2 Not yet recruiting
NCT07510334 2026-04-03
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Mayo Clinic
Phase 2 Not yet recruiting
NCT07494435 2026-03-27
Phase 2 Study of WGI-0301 Plus Nivolumab in Patients With HCC and RCC
Zhejiang Haichang Biotech Co., Ltd.
Phase 2 Not yet recruiting
NCT07492680 2026-03-25
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Bristol-Myers Squibb
Phase 2 Not yet recruiting
NCT07420439 2026-02-19
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
Intergroupe Francophone de Cancerologie Thoracique
Phase 2 Not yet recruiting
NCT07403877 2026-02-11
TORCH-OPTIMA
Fudan University
Phase 2 Not yet recruiting
NCT07369791 2026-01-28
NOBLE
National Health Research Institutes, Taiwan
Phase 2 Not yet recruiting
NCT07355205 2026-01-21
FLINN
Washington University School of Medicine
Phase 2 Not yet recruiting
NCT07219459 2025-10-21
GDFATHERHCC01
CatalYm GmbH
Phase 2 Not yet recruiting
NCT06692491 2024-11-18
SPRING
Peking University Shenzhen Hospital
Phase 2 Not yet recruiting
NCT06572722 2024-08-27
Perioperative Immunotherapy for NSCLC (ECTOP-1030)
Fudan University
Phase 2 Not yet recruiting
NCT06554613 2024-08-15
Olanzapine Impact on First-line Immunotherapy for Advanced EGFR-negative NSCLC
Second Affiliated Hospital of Nanchang University
Phase 2 Not yet recruiting
NCT05597800 2022-10-28
LUNGVIR
Universita di Verona
Phase 2 Not yet recruiting